GlaxoSmithKline Pharmaceuticals (500660) Q4 25/26 earnings summary

Executive summary

• Achieved profitable growth and margin expansion in FY26, with revenue and net profit increasing year-over-year.

• Audited standalone and consolidated financial results for FY26 were approved with unmodified audit opinions.

• Final dividend of ₹57 per share recommended for FY26, up from ₹54 in FY25, subject to AGM approval.

• PAT before exceptionals reached ₹1,010 crore, a 10% increase, marking the first-ever PAT above ₹1,000 crore.

• The company does not qualify as a Large Corporate under SEBI regulations as of 31 March 2026.

Financial highlights

• FY26 consolidated revenue: ₹3,821.67 crore, up from ₹3,749.21 crore in FY25; standalone revenue: ₹3,790.20 crore, up from ₹3,723.49 crore.

• FY26 consolidated net profit: ₹1,035.98 crore, up from ₹927.58 crore in FY25; standalone net profit: ₹1,011.82 crore, up from ₹919.06 crore.

• Total comprehensive income for FY26 was ₹1,028.44 crore, up from ₹924.92 crore in FY25.

• Q4FY26 revenue: ₹989 crore (+2% YoY); EBITDA: ₹347 crore (margin 35.1%, +90 bps); PAT: ₹275 crore (margin 28%, +90 bps).

• EPS excluding exceptionals at ₹59.6 (+10% YoY); ROCE at 61%.

Outlook and guidance

• Focused investments in innovative therapies and portfolio transformation expected to drive future growth.

• Continued emphasis on R&D acceleration and pipeline launches.

• The Board scheduled the 101st AGM for 30 June 2026, with dividend payment planned after approval.

• Ongoing optimization of field force productivity and cost management through AI-led initiatives.

• The company continues to monitor regulatory changes, especially regarding new Labour Codes, and will adjust accounting as needed.